Home > Boards > US Listed > Biotechs > Affimed Therapeutics (AFMD)

I know most people don't do their due

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BobDoleYahoo Member Profile
 
Followed By 52
Posts 788
Boards Moderated 0
Alias Born 07/11/17
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/5/2020 7:00:54 AM
Affimed Announces Two New Appointments to Its Supervisory Board GlobeNewswire Inc. - 8/5/2020 6:30:00 AM
Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020 GlobeNewswire Inc. - 8/4/2020 6:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/27/2020 4:37:35 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/10/2020 8:12:48 AM
Affimed Announces Annual General Meeting of Shareholders GlobeNewswire Inc. - 7/10/2020 6:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/23/2020 6:45:15 AM
Affimed Reports First Quarter 2020 Financial Results and Operational Progress GlobeNewswire Inc. - 6/23/2020 6:30:00 AM
Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed... GlobeNewswire Inc. - 6/22/2020 9:20:00 AM
Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of... GlobeNewswire Inc. - 6/17/2020 6:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/16/2020 10:56:13 AM
Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BM... GlobeNewswire Inc. - 6/16/2020 6:30:00 AM
Affimed Announces Appointment of Angus Smith as Chief Financial Officer GlobeNewswire Inc. - 6/11/2020 6:30:00 AM
Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting GlobeNewswire Inc. - 5/29/2020 8:05:00 AM
Affimed to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire Inc. - 5/28/2020 5:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/26/2020 4:30:57 PM
Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual... GlobeNewswire Inc. - 5/15/2020 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2020 4:33:10 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/13/2020 4:32:30 PM
Schedule 13g Edgar (US Regulatory) - 5/8/2020 8:10:57 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 4/28/2020 5:04:54 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/28/2020 6:49:07 AM
Affimed Reports 2019 Financial Results and Recent Operational Progress GlobeNewswire Inc. - 4/28/2020 6:35:00 AM
Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced ... GlobeNewswire Inc. - 4/16/2020 7:30:00 AM
Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28,... GlobeNewswire Inc. - 4/2/2020 6:30:00 AM
BobDoleYahoo   Thursday, 08/30/18 04:54:23 AM
Re: None
Post # of 234 
I know most people don't do their due diligence or read SEC filings, so I have done it for you. Let's compare $FATE to $AFMD

Pipelines are similar, in pre-clinical and phase 1:

$AFMD's pipeline: http://www.affimed.com/products.php
$FATE's pipeline: http://fatetherapeutics.com/pipeline/

$FATE's market cap: $664.53 million
$AFMD's market cap: 383.7 million

$FATE's cash on hand: $78.02 million
$AFMD's cash on hand: $55.23 million

$FATE's debt: $14.85 million
$AFMD's debt: $6.93 million

$FATE's last 10-Q states they think they'll have sufficient cash for next 12 months.
$AFMD's last 6-K quarterly report states they'll have sufficient cast through Q4, 2019 (the $96 million spread over a year, will most likely extend that duration out)

If $AFMD were to trade at $664 million market cap, that works out to be: $664.53 / 62.39 million shares = $10.65. However, the fact that Genentech is willing to foot most of the bill for the R&D costs AND they are receiving the $96 million over the period of a year, this should bring up the value significantly.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist